Littérature scientifique sur le sujet « Macromolecular recombinant drug »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Macromolecular recombinant drug ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Macromolecular recombinant drug"
Noh, Gyubin, Taekwang Keum, Jo-Eun Seo, Santosh Bashyal, Nyeon-Sik Eum, Min Kweon, Sooyeun Lee, Dong Sohn et Sangkil Lee. « Iontophoretic Transdermal Delivery of Human Growth Hormone (hGH) and the Combination Effect of a New Type Microneedle, Tappy Tok Tok® ». Pharmaceutics 10, no 3 (7 septembre 2018) : 153. http://dx.doi.org/10.3390/pharmaceutics10030153.
Texte intégralSelaković, Života, et Bogdan Šolaja. « ADVANCES IN TACKLING FILOVIRUSES ». Contributions, Section of Natural, Mathematical and Biotechnical Sciences 39, no 2 (28 décembre 2018) : 83. http://dx.doi.org/10.20903/csnmbs.masa.2018.39.2.127.
Texte intégralCallahan, Shellie M., Piyanuch Wonganan et Maria A. Croyle. « Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection ». Virology Journal 5, no 1 (2008) : 111. http://dx.doi.org/10.1186/1743-422x-5-111.
Texte intégralFerentz, Ann E., et Gerhard Wagner. « NMR spectroscopy : a multifaceted approach to macromolecular structure ». Quarterly Reviews of Biophysics 33, no 1 (février 2000) : 29–65. http://dx.doi.org/10.1017/s0033583500003589.
Texte intégralWu, Yu, Miora Rakotoarisoa, Borislav Angelov, Yuru Deng et Angelina Angelova. « Self-Assembled Nanoscale Materials for Neuronal Regeneration : A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery ». Nanomaterials 12, no 13 (30 juin 2022) : 2267. http://dx.doi.org/10.3390/nano12132267.
Texte intégralCoentro, João Q., Alessia di Nubila, Ulrike May, Stuart Prince, John Zwaagstra, Tero A. H. Järvinen et Dimitrios I. Zeugolis. « Dual drug delivery collagen vehicles for modulation of skin fibrosis in vitro ». Biomedical Materials 17, no 2 (1 mars 2022) : 025017. http://dx.doi.org/10.1088/1748-605x/ac5673.
Texte intégralTurbyfill, K. Ross, Kristen A. Clarkson, Edwin V. Oaks et Robert W. Kaminski. « From Concept to Clinical Product : A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and Evolution ». Vaccines 10, no 4 (1 avril 2022) : 548. http://dx.doi.org/10.3390/vaccines10040548.
Texte intégralSochacka-Ćwikła, Aleksandra, Marcin Mączyński et Andrzej Regiec. « FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review ». Cancers 14, no 1 (24 décembre 2021) : 87. http://dx.doi.org/10.3390/cancers14010087.
Texte intégralSellers, Drew L., Jamie M. Bergen, Russell N. Johnson, Heidi Back, John M. Ravits, Philip J. Horner et Suzie H. Pun. « Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration ». Proceedings of the National Academy of Sciences 113, no 9 (17 février 2016) : 2514–19. http://dx.doi.org/10.1073/pnas.1515526113.
Texte intégralGhosh, Samit, Prosenjit Sen, Mirella Ezban, Usha R. Pendurthi et L. Vijaya Mohan Rao. « Activity and Regulation of Long-Acting Factor VIIa Analogs. » Blood 110, no 11 (16 novembre 2007) : 3141. http://dx.doi.org/10.1182/blood.v110.11.3141.3141.
Texte intégralThèses sur le sujet "Macromolecular recombinant drug"
DELLA, CRISTINA Pietro Argeo. « Construction of a macromolecular recombinant drug for the targeted therapy of hematological malignancies ». Doctoral thesis, 2009. http://hdl.handle.net/11562/337455.
Texte intégralThe use of cytotoxic agents capable to selectively target surface molecules on a malignant cell is a promising approach for the treatment of cancer, especially hematologic malignacies. Immunotoxins, in particular, are polypeptides comprising an antibody-derived domain and a toxic portion, usually represented by a bacterial or plant toxin: the antibody specifically binds a target antigen and, following endocytosis, delivers the toxic payload to the interior of the cell, interfering with fundamental metabolic pathways. Among several leukemia/lymphoma-associated surface antigens, one of the most attractive molecular targets for this kind of therapeutic strategy is CD22, a membrane glycoprotein with coreceptor functions, whose expression is restricted to B lymphocytes. The present thesis describes the construction and characterization of a recombinant immunotoxin in which the binding domain is represented by a CD22-specific single-chain antibody fragment (scFv), while the cytotoxic activity is carried out by a truncated version of Pseudomonas aeruginosa Exotoxin A, a bacterial toxin that inhibits the mechanism of protein synthesis in eukaryotes. Through the molecular cloning of sequences coding for the variable domains of heavy and light chains (VH and VL, respectively) of an anti-CD22 murine monoclonal antibody, it was possible to assemble a plasmid construct coding for a scFv that was eventually produced in a bacterial expression system. Immunofluorecence analysis on CD22-positive cells and immunoenzymatic assays on the purified antigen proved that the antibody fragment maintains the binding specificity of the parental monoclonal antibody, exhibiting a fairly good affinity for CD22. The scFv was later genetically fused to the enzymatic domain of a bacterial toxin. The resulting immunotoxin was expressed in Escherichia coli and recovered from insoluble cytoplasmic aggregates after purification by affinity chromatography, with yields of 1-2 mg from a 1 litre culture. The binding properties of the recombinant immunotoxin are comparable to those of the scFv; V moreover, as ascertained through cell-proliferation assays, it can selectively poison CD22- expressing cells with an IC50 (i.e. concentration inhibiting 50% of the maximal cell proliferation) around 1-10 nM. It can be concluded that our anti-CD22 immunotoxin combines the binding qualities of the scFv antibody and the potent enzymatic activity of the bacterial toxin. After further characterization we will explore the opportunity to start a process of molecular optimization, aiming at the construction of a novel biotechnological drug for the treatment of hematological malignancies in humans.
Chapitres de livres sur le sujet "Macromolecular recombinant drug"
M. Skowron, Piotr, et Agnieszka Zylicz-Stachula. « DNA-FACE™ - An Escherichia coli-based DNA Amplification-Expression Technology for Automatic Assembly of Concatemeric ORFs and Proteins ». Dans Escherichia coli [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.101640.
Texte intégral« Macromolecules in Drug Discovery : Mass Spectrometry of Recombinant Proteins and Proteomics ». Dans Advances in Chromatography, Volume 47, 9–38. CRC Press, 2009. http://dx.doi.org/10.1201/9781420060379-3.
Texte intégral